Literature DB >> 31345525

Other Pituitary Conditions and Pregnancy.

Philippe Chanson1.   

Abstract

Diagnosis of lymphocytic hypophysitis occurring in the peripartum period is based on clinical and neuroradiological data and does not require a biopsy. Its course is generally spontaneously favorable in terms of mass effect but may require the administration of corticosteroids or even transsphenoidal resection. The course of pituitary deficiencies is highly variable; some cases recover over time, whereas others persist indefinitely. Sheehan syndrome is very rare in developed countries. Because agalactia and amenorrhea are often neglected, the diagnosis is generally delayed. Diabetes insipidus occurring in late pregnancy is caused by the increased placental production of vasopressinase and disappears after delivery.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune; Diabetes insipidus; Hypophysitis; Hypopituitarism; Pregnancy; Sheehan syndrome

Mesh:

Year:  2019        PMID: 31345525     DOI: 10.1016/j.ecl.2019.05.005

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

Review 1.  Adrenal insufficiency in pregnancy: Physiology, diagnosis, management and areas for future research.

Authors:  Jessica H Lee; David J Torpy
Journal:  Rev Endocr Metab Disord       Date:  2022-07-11       Impact factor: 9.306

Review 2.  Diagnosis and Management of Central Diabetes Insipidus in Adults.

Authors:  Maria Tomkins; Sarah Lawless; Julie Martin-Grace; Mark Sherlock; Chris J Thompson
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

3.  Acute Sheehan's syndrome manifesting initially with diabetes insipidus postpartum: a case report and systematic literature review.

Authors:  Gregor Leonhard Olmes; Erich-Franz Solomayer; Julia Caroline Radosa; Panagiotis Sklavounos; Philipp Agne; Stefan J Schunk; Bashar Haj Hamoud
Journal:  Arch Gynecol Obstet       Date:  2021-11-15       Impact factor: 2.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.